We are focused on the development and commercialization of biological medical devices manufactured using a proprietary perfusion decellularization technology that supports cellular integration.
Reprise Biomedical, Inc. was created in connection from a spin-off from Miromatrix Medical Inc.
Perfusion Decellularization Technology
Perfusion decellularization involves cannulating the main vasculature of the organ and perfusing a mild detergent solution through the native blood vessels to result in a preserved native scaffold containing the appropriate strength and microenvironment for cellular integration after it is implanted in the patient’s body
Surgical Soft Tissue Reinforcement
MIROMESH® is a non-crosslinked acellular surgical mesh, derived from the highly vascularized porcine liver. It is intended to be implanted to reinforce soft tissue and is also intended for implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement in plastic and reconstructive surgery.
Management for Chronic Wounds
MIRODERM® is a porcine liver-derived noncrosslinked acellular biologic wound matrix. It is indicated for the management of wounds, including: diabetic foot; venous and pressure ulcers; surgical and trauma wounds; and more.
MIRODERM Fenestrated Plus (Large expansion)MIRODERM Biologic Wound Matrix – For use in the management of wounds including diabetic foot ulcers, venous ulcers, pressure ulcers, and surgical and trauma wounds.
A Proven Team for Medical Devices
Reprise is led by experienced medical device commercialization management team with a record of success in biologic resorbable medical devices. We are guided by a Board of Directors with proven track records in the medical device industry with oversight and participation in a wide array of activities including new product development, manufacturing, and marketing.